Cancer Immunotherapy--revisited

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2011 Aug 2

PMID 21804596

Citations 170

Authors

W Joost Lesterhuis

John B A G Haanen

Cornelis J A Punt

Affiliations

Soon will be listed here.

Abstract

Our insight into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors. These include difficulties in the selection of the optimal dose and schedule, the methods of evaluation, and financial support. Although durable clinical remissions have been observed with various immunotherapeutic strategies, the percentage of patients who benefited from these interventions has remained too small to justify the general use of such strategies. However, the recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.

Citing Articles

Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges.

Ren L, Zhang D, Pang L, Liu S Front Bioeng Biotechnol. 2024; 12:1476737.

PMID: 39398642 PMC: 11466826. DOI: 10.3389/fbioe.2024.1476737.

Personalized prediction of immunotherapy response in lung cancer patients using advanced radiomics and deep learning.

Liao C, Chen Y, Wu Y, Chao H, Chiu H, Wang T Cancer Imaging. 2024; 24(1):129.

PMID: 39350284 PMC: 11440728. DOI: 10.1186/s40644-024-00779-4.

Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives.

Prades-Sagarra E, Yaromina A, Dubois L Clin Transl Radiat Oncol. 2024; 49:100852.

PMID: 39315059 PMC: 11418132. DOI: 10.1016/j.ctro.2024.100852.

RefAI: a GPT-powered retrieval-augmented generative tool for biomedical literature recommendation and summarization.

Li Y, Zhao J, Li M, Dang Y, Yu E, Li J J Am Med Inform Assoc. 2024; 31(9):2030-2039.

PMID: 38857454 PMC: 11339508. DOI: 10.1093/jamia/ocae129.

Targeted intracellular delivery of dimeric STINGa by two pHLIP peptides for treatment of solid tumors.

Moshnikova A, DuPont M, Iraca M, Klumpp C, Visca H, Allababidi D Front Pharmacol. 2024; 15:1346756.

PMID: 38495104 PMC: 10940318. DOI: 10.3389/fphar.2024.1346756.

References

Lesterhuis W, Aarntzen E, de Vries I, Schuurhuis D, Figdor C, Adema G . Dendritic cell vaccines in melanoma: from promise to proof?. Crit Rev Oncol Hematol. 2008; 66(2):118-34. DOI: 10.1016/j.critrevonc.2007.12.007. View

Lutsiak M, Semnani R, De Pascalis R, Kashmiri S, Schlom J, Sabzevari H . Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2004; 105(7):2862-8. DOI: 10.1182/blood-2004-06-2410. View

Bevan M . Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976; 143(5):1283-8. PMC: 2190184. DOI: 10.1084/jem.143.5.1283. View

Schuler-Thurner B, Schultz E, Berger T, Weinlich G, Ebner S, Woerl P . Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002; 195(10):1279-88. PMC: 2193752. DOI: 10.1084/jem.20012100. View

Nowak A, Lake R, Marzo A, Scott B, Heath W, Collins E . Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003; 170(10):4905-13. DOI: 10.4049/jimmunol.170.10.4905. View

Litzinger M, Fernando R, Curiel T, Grosenbach D, Schlom J, Palena C . IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007; 110(9):3192-201. PMC: 2200901. DOI: 10.1182/blood-2007-06-094615. View

Milas L, Mason K, Ariga H, Hunter N, Neal R, Valdecanas D . CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 2004; 64(15):5074-7. DOI: 10.1158/0008-5472.CAN-04-0926. View

Lesterhuis W, de Vries I, Aarntzen E, de Boer A, Scharenborg N, van de Rakt M . A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer. 2010; 103(9):1415-21. PMC: 2990614. DOI: 10.1038/sj.bjc.6605935. View

Shurin G, Tourkova I, Kaneno R, Shurin M . Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009; 183(1):137-44. PMC: 4005417. DOI: 10.4049/jimmunol.0900734. View

10.

Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E . Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005; 106(6):2018-25. DOI: 10.1182/blood-2005-02-0642. View

11.

Hoos A, Eggermont A, Janetzki S, Hodi F, Ibrahim R, Anderson A . Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010; 102(18):1388-97. PMC: 2943524. DOI: 10.1093/jnci/djq310. View

12.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

13.

Sylvester R, Brausi M, Kirkels W, Hoeltl W, da Silva F, Powell P . Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and.... Eur Urol. 2009; 57(5):766-73. PMC: 2889174. DOI: 10.1016/j.eururo.2009.12.024. View

14.

Bindon C, Czerniecki M, Ruell P, Edwards A, McCarthy W, Harris R . Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer. 1983; 47(1):123-33. PMC: 2011265. DOI: 10.1038/bjc.1983.15. View

15.

Den Brok M, Sutmuller R, van der Voort R, Bennink E, Figdor C, Ruers T . In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004; 64(11):4024-9. DOI: 10.1158/0008-5472.CAN-03-3949. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

18.

Kawakami Y, Eliyahu S, Delgado C, Robbins P, Rivoltini L, Topalian S . Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994; 91(9):3515-9. PMC: 43610. DOI: 10.1073/pnas.91.9.3515. View

19.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

20.

Schuster S, Neelapu S, Gause B, Janik J, Muggia F, Gockerman J . Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011; 29(20):2787-94. PMC: 3139394. DOI: 10.1200/JCO.2010.33.3005. View